^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aspirin

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    COX inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    aspirin
    5d
    Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (clinicaltrials.gov)
    P1, N=24, Completed, Laboratorios Silanes S.A. de C.V.
    New P1 trial
    |
    aspirin
    7d
    OPTION2: IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (clinicaltrials.gov)
    P4, N=2846, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Dec 2028 | Trial primary completion date: May 2026 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    aspirin
    10d
    CONCLAVE: Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement (clinicaltrials.gov)
    P4, N=1058, Not yet recruiting, Asan Medical Center
    New P4 trial
    |
    aspirin
    12d
    Distinct Tumor Infiltrating Immune Cell Profiles in Mice by Non-Steroidal Anti-Inflammatory Drugs (Aspirin and Naproxen) During TMPRSS2-ERG (Fusion)-Driven and Non-Fusion Driven Prostate Cancer. (PubMed, Mol Carcinog)
    Both models showed increased B-cell infiltration independent of NSAID efficacy, and no clear correlation was observed between plasma-cell presence and treatment response. Collectively, our findings offer new insight into NSAID-mediated immunomodulation in TMPRSS2-ERG fusion-driven PCa; however, further in-depth immune subtyping and spatial mapping could fully delineate the immunological mechanisms driving NSAID responsiveness.
    Preclinical • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • ERG (ETS Transcription Factor ERG) • GZMB (Granzyme B) • TMPRSS2 (Transmembrane serine protease 2) • FOXP3 (Forkhead Box P3) • IGKC (Immunoglobulin Kappa Constant)
    |
    TMPRSS2-ERG fusion
    |
    aspirin
    15d
    Evaluating the causal effects of circulating plasma proteins on the risk of malignant neoplasms of bone and articular cartilage. (PubMed, J Int Med Res)
    Further co-localisation analysis revealed that ADAMTS5, GNLY and PCSK7 shared genetic variants associated with the risk of malignant neoplasms of bone and articular cartilage. Molecular docking analysis indicated that compounds such as aspirin and vitamin E exhibited low binding energies with GNLY, PCSK7 and ADAMTS5, suggesting potential therapeutic intervention opportunities.ConclusionThis study identified three proteins (GNLY, PCSK7 and ADAMTS5) associated with a high risk of malignant neoplasms of bone and articular cartilage through Mendelian randomisation and co-localisation analyses, providing novel molecular evidence for early diagnosis, risk assessment and potential targeted therapies for malignant neoplasms of bone and articular cartilage.
    Journal
    |
    PD-L2 (Programmed Cell Death 1 Ligand 2) • CNTN1 (Contactin 1) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
    |
    aspirin
    16d
    PANTHEON: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (clinicaltrials.gov)
    P3, N=2570, Recruiting, Montreal Heart Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    16d
    WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov)
    P4, N=2476, Active, not recruiting, University of Florida | Completed --> Active, not recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jan 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    atorvastatin • aspirin
    16d
    ASPIK French: Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (clinicaltrials.gov)
    P3, N=264, Recruiting, University Hospital, Rouen | Trial completion date: Jul 2024 --> Jul 2028 | Trial primary completion date: Jul 2024 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    PI3K (Phosphoinositide 3-kinases)
    |
    aspirin
    17d
    Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain (clinicaltrials.gov)
    P4, N=25, Not yet recruiting, Mayo Clinic | Trial completion date: Dec 2028 --> Jun 2027 | Initiation date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    aspirin
    17d
    ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (clinicaltrials.gov)
    P4, N=240, Active, not recruiting, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Mar 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    aspirin
    17d
    APHP230836: SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss (2024-513710-35-00)
    P2/3, N=142, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P2/3 trial
    |
    aspirin